OFIX
Orthofix Medical Inc.15.55
-0.16-1.02%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Details LRP delay, Biologics refocus
Q&A pinned the one-year LRP extension squarely on Spine channel optimization taking longer to bed in, yet stressed its payoff with top 30 U.S. distributors now driving 75% of sales for better predictability. Management revealed a Biologics reboot via leadership reshuffles, aiming for market-rate U.S. performance post-transition dip. They quantified Q1 BGT's 1% CMS pilot headwind and $1-2M 2026 tariff hit, both baked into guidance. Free cash flow stays positive excluding legal settlements, with Q3 accrual noted. Channel fix took time. Answers largely reaffirmed prepared outlook conviction, with investors eyeing Biologics traction and VIRATA ramp.
Key Stats
Market Cap
615.77MP/E (TTM)
-Basic EPS (TTM)
-3.03Dividend Yield
0%Recent Filings
8-K
Orthofix Q4 sales up 2%
Orthofix reported Q4 2025 net sales of $219.9M, up 2% YoY, with pro forma net sales excluding M6 discs at $218.6M, up 3% on constant currency. Global Spine Fixation surged 10%, Bone Growth Therapies 7%, U.S. Limb Reconstruction 8%, driving pro forma adjusted EBITDA to $29.2M—13.4% margin, up 230 bps. Q4 free cash flow hit $16.8M. Guides 2026 sales to $850M-$860M, adjusted EBITDA $95M-$98M, positive FCF.
10-K
FY2025 results
Orthofix Medical posted FY2025 net sales of $822.3M, up 2.9% y/y, with pro forma sales excluding discontinued M6 discs at $811.9M, up 4.1% on constant currency. Global Spine drove gains via 10.1% y/y Spine Fixation growth and 5.9% Bone Growth Therapies expansion, while Limb Reconstruction rose 8.4% reported (15.8% U.S.). Q4 momentum shone in U.S. channels, yet M6 discontinuation hit biologics; margins held at 68.8%. Cash stood at $85.1M year-end, bolstered by $33.3M operating cash flow. No annual guidance disclosed. Integration risks from 2023 SeaSpine merger linger.
10-Q
Q3 FY2025 results
Orthofix posted Q3 net sales of $205.6M, up 4.6% y/y, with Global Orthopedics surging 10.1% y/y while Global Spine edged 3.6% higher; gross margin expanded to 72.2% from 68.7%, yet operating loss narrowed just 10% to $(17.0)M as SG&A jumped 13.8% on litigation costs. YTD sales rose 3.2% to $602.4M, but net loss widened to $(90.0)M from $(96.9)M due to M6 impairments in acquisition-related line. Cash fell to $62.9M atop $157.2M term debt, though ops cash hit $5.7M and FCF improved (derived). Steady revenue grind continues. Litigation with former executives drags.
8-K
Q3 sales up 6%, EBITDA expands
Orthofix posted Q3 net sales of $205.6M, up 4.6% reported but 6% pro forma constant currency excluding discontinued M6 lines, with U.S. Spine Fixation surging 8% and Orthopedics 19%. Pro forma adjusted EBITDA hit $24.6M, expanding margins 233 bps via cost discipline, while free cash flow turned positive at $2.5M. Momentum builds. Guidance narrows to $810M-$814M pro forma sales, $84M-$86M EBITDA.
10-Q
Q2 FY2025 results
Orthofix posted Q2 net sales of $203.1M, up 2.3% y/y yet flat q/q (derived), with Global Orthopedics surging 8.9% y/y on TrueLok/Fitbone strength while Spine edged 1.1% higher despite M6 disc discontinuation. Gross margin expanded to 68.7% from 67.8% y/y, narrowing the operating loss to $16.0M from $24.9M, though net loss widened slightly to $14.1M from $33.4M due to litigation costs and M6 impairments exceeding other income gains. Cash fell to $65.6M from $83.2M year-end amid $6.8M operating outflow, yet free cash flow improved (derived); $157.0M term debt steady with full covenant compliance. Ongoing securities litigation poses execution risk.
AMIX
Autonomix Medical, Inc.
0.63-0.03
CNMD
CONMED Corporation
39.20-1.12
ENOV
Enovis Corporation
26.07-0.47
FZMD
Fuse Medical, Inc.
0.07+0.00
GMED
Globus Medical, Inc.
85.79-0.71
KIDS
OrthoPediatrics Corp.
17.91-0.08
OSSFF
EMBLA MEDICAL
5.33+0.00
SIBN
SI-BONE, Inc.
19.42+1.01
SYK
Stryker Corporation
351.69-3.62
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52